Tiziana Life Sciences Ltd

NasdaqCM:TLSA Stock Report

Market Cap: US$84.5m

Tiziana Life Sciences Past Earnings Performance

Past criteria checks 0/6

Tiziana Life Sciences's earnings have been declining at an average annual rate of -4.3%, while the Biotechs industry saw earnings growing at 19.3% annually.

Key information

-4.3%

Earnings growth rate

-2.8%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth raten/a
Return on equity-740.1%
Net Marginn/a
Last Earnings Update30 Jun 2024

Recent past performance updates

No updates

Recent updates

Will Tiziana Life Sciences (NASDAQ:TLSA) Spend Its Cash Wisely?

Sep 19
Will Tiziana Life Sciences (NASDAQ:TLSA) Spend Its Cash Wisely?

We're Keeping An Eye On Tiziana Life Sciences' (NASDAQ:TLSA) Cash Burn Rate

Jun 03
We're Keeping An Eye On Tiziana Life Sciences' (NASDAQ:TLSA) Cash Burn Rate

Will Tiziana Life Sciences (NASDAQ:TLSA) Spend Its Cash Wisely?

Jan 16
Will Tiziana Life Sciences (NASDAQ:TLSA) Spend Its Cash Wisely?

Tiziana Life rises 11% after submitting application to begin human trial of Alzheimer's intranasal therapy

Oct 12

Tiziana chief medical officer further increases holdings in company

Sep 23

Tiziana Life Sciences executive chairman further raises stake in company

Sep 16

Tiziana executive chairman raises stake in company again, buys more shares

Aug 25

Tiziana Life Sciences discloses share purchase by executive chairman

Aug 17

Is Tiziana Life Sciences (NASDAQ:TLSA) In A Good Position To Deliver On Growth Plans?

Aug 15
Is Tiziana Life Sciences (NASDAQ:TLSA) In A Good Position To Deliver On Growth Plans?

Tiziana Life Sciences CEO Kunwar Shailubhai resigns

Jul 15

Revenue & Expenses Breakdown

How Tiziana Life Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:TLSA Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 240-1487
31 Mar 240-1698
31 Dec 230-18108
30 Sep 230-19108
30 Jun 230-20109
31 Mar 230-17611
31 Dec 220-15213
30 Sep 220-13114
30 Jun 220-11015
31 Mar 220-17714
31 Dec 210-231413
30 Sep 210-312312
30 Jun 210-383111
31 Mar 210-32288
31 Dec 200-26246
30 Sep 200-18164
30 Jun 200-1073
31 Mar 200-1073
31 Dec 190-964
30 Sep 190-864
30 Jun 190-855
31 Mar 190-855
31 Dec 180-846
30 Sep 180-846
30 Jun 180-956
31 Mar 180-956
31 Dec 170-946
30 Sep 170-1156
30 Jun 170-1266
31 Mar 170-1055
31 Dec 160-954
30 Sep 160-945
30 Jun 160-936
31 Mar 160-1148
31 Dec 150-1339
30 Sep 150-1147
30 Jun 150-945
31 Mar 150-733

Quality Earnings: TLSA is currently unprofitable.

Growing Profit Margin: TLSA is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: TLSA is unprofitable, and losses have increased over the past 5 years at a rate of 4.3% per year.

Accelerating Growth: Unable to compare TLSA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TLSA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).


Return on Equity

High ROE: TLSA has a negative Return on Equity (-740.05%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 09:59
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Tiziana Life Sciences Ltd is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mayank MamtaniB. Riley Securities, Inc.
Robin CampbellEquity Development Limited
Raghuram SelvarajuH.C. Wainwright & Co.